 |
인쇄하기
취소
|
Bukwang beset by groundless M&A rumors
Bukwang Pharm is concerned over a drop in its stock prices due to rumors of its takeover by a multinational pharmaceutical firm.
The company has repeatedly denied any M&A scenarios, but its stock prices plummeted from 19,000 won to 15,000 won, as the rumors proved groundless.
“We expect our stock prices to rebound in the months to come, given the robust sales backed by flagship products,”...
The company has repeatedly denied any M&A scenarios, but its stock prices plummeted from 19,000 won to 15,000 won, as the rumors proved groundless.
“We expect our stock prices to rebound in the months to come, given the robust sales backed by flagship products,”...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.